celecoxib has been researched along with Epithelial Ovarian Cancer in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of our study was to investigate the therapeutic potential of Celecoxib for epithelial ovarian cancer, especially on cellular morphological changes, proliferation invasion and epithelial-mesenchymal transition (EMT)." | 7.81 | Celecoxib induces epithelial-mesenchymal transition in epithelial ovarian cancer cells via regulating ZEB1 expression. ( Li, C; Liu, P; Liu, R; Pang, Y; Xu, X; Zheng, J; Zheng, Q, 2015) |
| "Celecoxib was to be continued after DC termination up to 3 years." | 6.77 | A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the Do ( de Graaf, H; de Munck, L; Erdkamp, FLG; Hoekman, K; Hollema, H; Lalisang, RI; Polee, M; Reyners, AKL; Schaapveld, M; Smit, WM; van Vugt, MATM; Willemse, PHB; Wymenga, ANM, 2012) |
| "However, the role of COX-2 in epithelial ovarian cancer (EOC), and its mechanistic details, remain poorly understood." | 5.48 | COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation. ( Li, CH; Li, XW; Wang, QY; Wang, YP, 2018) |
| "The purpose of our study was to investigate the therapeutic potential of Celecoxib for epithelial ovarian cancer, especially on cellular morphological changes, proliferation invasion and epithelial-mesenchymal transition (EMT)." | 3.81 | Celecoxib induces epithelial-mesenchymal transition in epithelial ovarian cancer cells via regulating ZEB1 expression. ( Li, C; Liu, P; Liu, R; Pang, Y; Xu, X; Zheng, J; Zheng, Q, 2015) |
| "Celecoxib was to be continued after DC termination up to 3 years." | 2.77 | A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the Do ( de Graaf, H; de Munck, L; Erdkamp, FLG; Hoekman, K; Hollema, H; Lalisang, RI; Polee, M; Reyners, AKL; Schaapveld, M; Smit, WM; van Vugt, MATM; Willemse, PHB; Wymenga, ANM, 2012) |
| "Advanced epithelial ovarian cancer (EOC) is associated with dismal outcome and progression-free survival (PFS) shortens with each subsequent relapse." | 1.51 | Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis. ( Bhatla, N; Khurana, S; Kumar, L; Kumar, S; Malik, PS; Ray, MD; Sharma, A, 2019) |
| "However, the role of COX-2 in epithelial ovarian cancer (EOC), and its mechanistic details, remain poorly understood." | 1.48 | COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation. ( Li, CH; Li, XW; Wang, QY; Wang, YP, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, A | 1 |
| Malik, PS | 1 |
| Khurana, S | 1 |
| Kumar, S | 1 |
| Bhatla, N | 1 |
| Ray, MD | 1 |
| Kumar, L | 1 |
| Wang, YP | 1 |
| Wang, QY | 1 |
| Li, CH | 1 |
| Li, XW | 1 |
| Gupta, R | 1 |
| Cristea, M | 1 |
| Frankel, P | 1 |
| Ruel, C | 1 |
| Chen, C | 1 |
| Wang, Y | 1 |
| Morgan, R | 1 |
| Leong, L | 1 |
| Chow, W | 1 |
| Koczywas, M | 1 |
| Koehler, S | 1 |
| Lim, D | 1 |
| Luu, T | 1 |
| Martel, C | 1 |
| McNamara, M | 1 |
| Somlo, G | 1 |
| Twardowski, P | 1 |
| Yen, Y | 1 |
| Idorenyi, A | 1 |
| Raechelle, T | 1 |
| Carroll, M | 1 |
| Chung, V | 1 |
| Liu, R | 1 |
| Zheng, J | 1 |
| Li, C | 1 |
| Pang, Y | 1 |
| Zheng, Q | 1 |
| Xu, X | 1 |
| Liu, P | 1 |
| van Kruchten, M | 1 |
| van der Marel, P | 1 |
| de Munck, L | 2 |
| Hollema, H | 2 |
| Arts, H | 1 |
| Timmer-Bosscha, H | 1 |
| de Vries, E | 1 |
| Hospers, G | 1 |
| Reyners, A | 1 |
| Reyners, AKL | 1 |
| Erdkamp, FLG | 1 |
| Smit, WM | 1 |
| Hoekman, K | 1 |
| Lalisang, RI | 1 |
| de Graaf, H | 1 |
| Wymenga, ANM | 1 |
| Polee, M | 1 |
| van Vugt, MATM | 1 |
| Schaapveld, M | 1 |
| Willemse, PHB | 1 |
3 trials available for celecoxib and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents | 2019 |
Hormone receptors as a marker of poor survival in epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2015 |
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the Do
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2012 |
3 other studies available for celecoxib and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Com | 2019 |
COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation.
Topics: Blotting, Western; Cadherins; Carcinoma, Ovarian Epithelial; Celecoxib; Cell Line, Tumor; Cyclooxyge | 2018 |
Celecoxib induces epithelial-mesenchymal transition in epithelial ovarian cancer cells via regulating ZEB1 expression.
Topics: Cadherins; Carcinoma, Ovarian Epithelial; Celecoxib; Cell Line, Tumor; Cell Proliferation; Down-Regu | 2015 |